Neoolife, Inc. is a pre-clinical stage Bio-MedTech start-up based in the United States and with a presence in Europe. Neoolife includes an international, multidisciplinary team with more than 130 years of cumulative experience in biomedical technology and device therapy. Firm's business team has a recognized track of leadership in both large corporations and start-ups. Neoolife worldwide recognized bio/chemical/mechanical engineers and cardiovascular physicians have a long-lasting involvement in the research & development, clinical, and academic fields of cardiovascular disease. Company focuses on tissue-engineered Biomimetic Heart Valves (BMHV) and tissue-engineered Biomimetic Cardiovascular Patches (BMCP) that enable endogenous in situ tissue regeneration. Neoolife technology is used for percutaneous and surgical applications. Neoolife is also developing unique solutions for the percutaneous treatment of heart valve disease, i.e., tricuspid valve regurgitation. Neoolife polymeric tissue-engineered biomimetic products are durable, non-thrombogenic, and resistant to calcification.
